Routes of Administration in Oncology and Other Therapeutic Areas

This technical report examines the evolving role of routes of administration (RoA) in the context of oncology, immunology, neurology, and metabolic diseases. It outlines how RoA has transitioned from a mere operational detail to a strategic lever influencing trial feasibility, patient experience, and product lifecycle management. The report presents clinical-program benchmarks, revealing that the historical approval rates vary across therapeutic areas, with intravenous (IV) administration still dominating oncology, while subcutaneous (SC) routes are gaining traction in immunology and metabolic diseases. The analysis highlights the reasons for these trends, including patient convenience, treatment efficacy, and market strategies. It also discusses the implications of these shifts for clinical development leaders, portfolio strategists, and business development teams, emphasizing the importance of aligning RoA decisions with the biology of treatments and the realities of patient care. The report concludes that understanding RoA dynamics is essential for effective decision-making in drug development and commercialization.